

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/

<b>Name of entity</b>	<b>Noxopharm Limited (ASX: NOX)</b>
<b>ABN</b>	<b>50 608 966 123</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Frederik Bart
<b>Date of last notice</b>	15 December 2020

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Bart Superannuation Pty Limited atf 4F Investments Super Fund (member and director of trustee)
<b>Date of change</b>	31 May 2020
<b>No. of securities held prior to change</b>	<u>DIRECT</u> 1. 2,538,462 Ordinary shares 2. 846,154 Listed Options Expiry, 18/06/2023, Exercisable @ \$0.30 3. 3,000,000 Unlisted Options, Exercisable @0.315, Vesting in three different tranches subject to performance milestones and Expiry 15 December 2022.  <u>INDIRECT (BART SUPERANNUATION PL)</u> 4. 0 Ordinary shares
<b>Class</b>	4. Ordinary shares
<b>Number acquired</b>	4. 3,080,189 Ordinary shares
<b>Number disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$1,580,137
<b>No. of securities held after change</b>	<u>DIRECT</u> <ol style="list-style-type: none"> <li>1. 2,538,462 Ordinary shares</li> <li>2. 846,154 Listed Options Expiry, 18/06/2023, Exercisable @ \$0.30</li> <li>3. 3,000,000 Unlisted Options, Exercisable @0.315, Vesting in three different tranches subject to performance milestones and Expiry 15 December 2022.</li> </ol> <u>INDIRECT (BART SUPERANNUATION PL)</u> <ol style="list-style-type: none"> <li>4. 3,080,189 Ordinary shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The securities are being issued as part of conversion of the Amended Loan Agreement, as approved by Shareholders at the 2021 Extraordinary General Meeting on 31 May 2021.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

---

+ See chapter 19 for defined terms.

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.